"Wasn't there a later inclusion of sites in the USA....."

Not that I am aware of. 

"and didn't the sites in HL regional deal fall behind enrollment in China? ???? I think it was about three or four months before the original trial finish date."

Resverlogix announced that BETonMACE had exceeded target enrollment of 2400 patients about 13 months ago in mid-March 2018. Resverlogix stated at the AGM last year that the China/Taiwan enrollment was left open past March 2018 and ended in June 2018. The final enrollment stated in various sources is 2425 patients. Put it all together and no more than 25 patients were enrolled after March 2018. Resverlogix stated that 6 months is the minimum required dosing period in BETonMACE. So nothing about these last 25 or less patients should be holding up the completion of the BETonMACE trial, in my opinion.

BearDownAZ